UTI Mid Cap Fund · Regular · Growth
NAV
₹300.5614
as of 30 Sept 2026
Expense Ratio
1.95%
AUM
₹11,737 Cr
Lumpsum returns (CAGR)
- 1Y
- +2.01%
- 3Y
- +9.71%
- 5Y
- +10.17%
- Since Inception
- +16.29%
SIP returns (XIRR)
- 1Y
- +0.14%
- 3Y
- +4.28%
- 5Y
- +9.67%
- Since Inception
- +15.54%
Returns calculated from 22 August 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Oct 2016 – Sept 2026)
A ₹5,000 monthly SIP for the last 10 years (Oct 2016 – Sept 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹12,22,919 today — ₹5,95,000 invested, 14.0% XIRR.
₹5,95,000
Invested
₹12,22,919
Value today
14.0%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Oct 2016 – Sept 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,19,040 today (12.3% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Oct 2016 would still hold ₹19,67,479.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹12,22,919 in this fund vs ₹14,87,839 in the benchmark — underperformance of ₹2,64,920.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Oct 2016 – Sept 2026) (22 Mar 2020) would be ₹4,28,193 today (4.28×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.43
Sharpe Ratio
+0.04
Alpha
0.09
Beta
0.41
Sortino
14.68%
Std Dev
-14.10%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026- Pharmaceuticals & Biotechnology9.70%
- Banks8.61%
- Industrial Products8.20%
- Retailing6.42%
- Finance6.26%
- Consumer Durables5.96%
- IT - Software5.82%
- Electrical Equipment5.70%
- Auto Components5.34%
- Capital Markets5.18%
- Chemicals & Petrochemicals3.20%
- Financial Technology (Fintech)3.08%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Mid Cap Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Portfolio holdings
- 1Coforge Ltd3.26%
- 2Pb Fintech Ltd3.08%
- 3Au Small Finance Bank Ltd2.76%
- 4Apl Apollo Tubes Ltd2.43%
- 5Hero Motocorp Ltd.2.17%
- 6Aurobindo Pharma Ltd.2.15%
- 7Federal Bank Ltd.2.08%
- 8Polycab India Ltd2.07%
- 9Ajanta Pharma Ltd.2.07%
- 10Shriram Finance Ltd2.00%
What this fund does
UTI Mid Cap Fund · Regular · Growth seeks to generate long-term capital appreciation by investing in mid-cap companies — ranked 101st to 250th by market capitalisation. These companies offer a balance of growth potential and relative stability, with wider price swings than large-caps.
About This Fund
UTI Mid Cap Fund · Regular · Growth is a Mid Cap mutual fund offered by UTI Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹11,737 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against Nifty Midcap 150 TRI. The current expense ratio is 1.95%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations